Skip to main content
TIP graphic

Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.

Radu Custelcean's sustainable chemistry for capturing carbon dioxide from air has been licensed to Holocene. Credit: Genevieve Martin/ORNL, U.S. Dept. of Energy

An innovative and sustainable chemistry developed at ORNL for capturing carbon dioxide has been licensed to Holocene, a Knoxville-based startup focused on designing and building plants that remove carbon dioxide

Oak Ridge National Laboratory led a team of scientists to design a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and future virus outbreaks. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.

Technology Innovation Program

Five technologies invented by scientists at the Department of Energy’s Oak Ridge National Laboratory have been selected for targeted investment through ORNL’s Technology Innovation Program.

Jim Szybist, Propulsion Science section head at ORNL, is applying his years of alternative fuel combustion and thermodynamics research to the challenge of cleaning up the hard-to-decarbonize, heavy-duty mobility sector. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy.

What’s getting Jim Szybist fired up these days? It’s the opportunity to apply his years of alternative fuel combustion and thermodynamics research to the challenge of cleaning up the hard-to-decarbonize, heavy-duty mobility sector — from airplanes to locomotives to ships and massive farm combines.

ORNL researchers proved that COVID-19 vaccines can be kept ultra-cool for an extended period in a retrofitted commercial storage container, providing a resource for safe delivery to remote locations. Credit: ORNL, U.S. Dept. of Energy

Oak Ridge National Laboratory researchers have retrofitted a commercial refrigeration container designed to ensure COVID-19 vaccines remain at ultra-low temperatures during long transport and while locally stored.

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus. Credit: Michelle Lehman/ORNL, U.S. Dept. of Energy

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

Scientists genetically engineered bacteria for itaconic acid production, creating dynamic controls that separate microbial growth and production phases for increased efficiency and acid yield. Credit: NREL

A research team led by Oak Ridge National Laboratory bioengineered a microbe to efficiently turn waste into itaconic acid, an industrial chemical used in plastics and paints.

Kashif Nawaz, researcher and group leader for multifunctional equipment integration in buildings technologies, is developing a platform for the direct air capture of carbon dioxide that can be retrofitted to existing rooftop heating, ventilation and air conditioning units.  Credit: ORNL/U.S. Dept. of Energy

When Kashif Nawaz looks at a satellite map of the U.S., he sees millions of buildings that could hold a potential solution for the capture of carbon dioxide, a plentiful gas that can be harmful when excessive amounts are released into the atmosphere, raising the Earth’s temperature.

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.